Is BeiGene, Ltd.'s (NASDAQ:BGNE) Shareholder Ownership Skewed Towards Insiders?

A look at the shareholders of BeiGene, Ltd. (NASDAQ:BGNE) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

BeiGene is a pretty big company. It has a market capitalization of US$17b. Normally institutions would own a significant portion of a company this size. In the chart below, we can see that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about BeiGene.

View our latest analysis for BeiGene

ownership-breakdown
NasdaqGS:BGNE Ownership Breakdown June 9th 2022

What Does The Institutional Ownership Tell Us About BeiGene?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that BeiGene does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at BeiGene's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
NasdaqGS:BGNE Earnings and Revenue Growth June 9th 2022

It would appear that 11% of BeiGene shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's largest shareholder is Amgen Inc., with ownership of 18%. With 11% and 11% of the shares outstanding respectively, Baker Bros. Advisors LP and Hillhouse Investment Management, Ltd. are the second and third largest shareholders. In addition, we found that John Oyler, the CEO has 3.8% of the shares allocated to their name.

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.